I do not see regulatory strategy as a dossier-only function. Early regulatory choices influence the product profile, evidence plan, timing, cost and flexibility available to the wider business. Market access and portfolio teams, in turn, shape which regulatory outcomes are commercially meaningful.
Three disciplines, one investment decision
A portfolio decision becomes stronger when it answers four connected questions: Can the product progress through an appropriate regulatory pathway? Can it reach the intended market under a credible access logic? Does it strengthen the portfolio rather than merely add another item? Can the organization and its partners execute the plan?
None of these questions should be answered in isolation. A technically possible route may not support the intended value proposition. An attractive market may require evidence, timing or investment that changes the portfolio case. A strategically relevant product may still be unsuitable if the operating model cannot support it.
Start with a shared opportunity thesis
I prefer to state the opportunity in one concise decision record: the target role of the product, the intended market segment, the core evidence, the proposed regulatory route, the access hypothesis, the portfolio rationale, the commercial assumptions and the material uncertainties.
This forces the team to distinguish evidence from optimism. It also creates a common reference when assumptions change, rather than allowing each function to continue working from a different version of the opportunity.
Test four kinds of fit
Regulatory fit
Is the target product profile supported by the available evidence? Are the important gaps, dependencies and decision points visible? Is the proposed sequence practical?
Access fit
Who needs to recognize the product’s value, through which channel or decision process, and on what evidence? What would limit adoption even if the regulatory plan succeeds?
Portfolio fit
Does the product deepen a priority area, complement existing capabilities, improve partner relevance or create a defensible reason to invest? Opportunity volume alone is not a portfolio strategy.
Execution fit
Are ownership, resources, partner capabilities, supply assumptions and launch dependencies realistic? A strategy that cannot be operated is not yet a strategy.
The purpose of integration is not to make every function agree. It is to make trade-offs explicit before resources are committed.
Sequence decisions, not departments
Cross-functional work often fails when it is organized as a relay: one team finishes, then hands the opportunity to the next. I prefer decision-based sequencing. At each gate, the right functions examine the same assumptions and decide what evidence or action is needed next.
Early gates may focus on strategic fit and critical feasibility. Later gates can test evidence readiness, access logic, economics, partner readiness and launch dependencies in more detail. The level of analysis should grow with the level of commitment.
Portfolio discipline means being willing to stop
A good framework does not only help select products; it helps stop weak opportunities before they absorb disproportionate time. A pause or no-go decision is valuable when it is based on transparent criteria and leaves a clear record of what would need to change.
When regulatory strategy, market access and portfolio logic operate from the same evidence base, decisions become clearer, revisions become faster and accountability becomes easier to maintain.